$KBIO Long
12.5.2016- KBIO currently trading at 4.25. Potential once they receive PRV (Priority Review Voucher) for Benznidazole possibility for trading at $5-6. Stock jumped about $1 due to the Letter to Stakeholders by Dr. Cameron Durrant. I expect this stock to rise.
Disclosure: I am long KBIO
SEE MORE: globenewswire.com/news-release/2016/12/05/895029/0/en/KaloBios-Highlights-Priority-Milestones-in-Letter-to-Stakeholders.html
Disclosure: I am long KBIO
SEE MORE: globenewswire.com/news-release/2016/12/05/895029/0/en/KaloBios-Highlights-Priority-Milestones-in-Letter-to-Stakeholders.html
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.